Statistik Asas
| CIK | 1567529 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kamada Ltd.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of September 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principa |
|
| September 2, 2025 |
Kamada to Participate in Upcoming September Investor Conferences Exhibit 99.1 Kamada to Participate in Upcoming September Investor Conferences REHOVOT, Israel, and Hoboken, NJ, – September 2, 2025 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Office |
|
| August 13, 2025 |
Exhibit 99.1 Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance ● First Half 2025 Total Revenues were $88.8 Million, up 11% Year-over-Year; Revenues for 2025 Second Quarter were $44.8 Million, up 5% Year-over-Year ● First Half 2025 Adjusted EBITDA of |
|
| August 13, 2025 |
Exhibit 99.3 KAMADA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2025 TABLE OF CONTENTS Page Condensed Consolidated interim Statements of Financial Position F-2 Condensed Consolidated interim Statements of Profit or Loss and Other Comprehensive Income F-3 Condensed Consolidated interim Statements of Changes in Equity F-4 - F-6 Condensed Consolidated interim Statements of |
|
| August 13, 2025 |
Exhibit 99.2 August 2025 H1/2025 & Q2/2025 Investors Call NASDAQ: KMDA; TASE: KMDA.TA FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials . This present |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal e |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal e |
|
| August 11, 2025 |
Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas Exhibit 99.1 Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas ● Houston Center Cleared to Commence Commercial Sales of Normal Source Plasma ● State of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its Full Capacity ● Center is Structured to Collect |
|
| August 6, 2025 |
Exhibit 99.1 Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025 Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, NJ – August 6, 2025 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a lea |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal e |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of June 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exe |
|
| June 17, 2025 |
Exhibit 99.1 Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East Rehovot, Israel, and Hoboken, NJ – June 17, 2025 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exec |
|
| May 14, 2025 |
Exhibit 99.1 Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability ● Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year Increase ● First Quarter Adjusted EBITDA of $11.6 Million, Up 54% Year-over-Year ● Strong Financial Position to Accelerate Growth Through M&A and/or In-licensin |
|
| May 14, 2025 |
Exhibit 99.2 May 2025 First Quarter March 31, 2025 Investors Call FORWARD - LOO K I NG STATEM ENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials . This presentation contains f |
|
| May 14, 2025 |
Exhibit 99.3 KAMADA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF MARCH 31, 2025 TABLE OF CONTENTS Page Condensed Consolidated interim Statements of Financial Position F-2 Condensed Consolidated interim Statements of Profit or Loss and Other Comprehensive Income F-3 Condensed Consolidated interim Statements of Changes in Equity F-4 - F-5 Condensed Consolidated interim Statements o |
|
| May 7, 2025 |
Exhibit 99.1 Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025 Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, NJ – May 7, 2025 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived f |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exec |
|
| May 5, 2025 |
Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM® Exhibit 99.1 Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM® · Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ Transplantation · A Total of 10 Studies will be Conducted in Collaboration with Leading U.S. Physicians, Primarily as Investigator-Initiated Studies (IIS) · Result |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exec |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal ex |
|
| March 24, 2025 |
Exhibit 99.1 Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders REHOVOT, Israel, and HOBOKEN, NJ – March 24, 2025 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today th |
|
| March 19, 2025 |
Exhibit 99.1 Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas ● New Plasma Collection Center in San Antonio has Planned Annual Collection Capacity of Approximately 50,000 Liters ● Center Will Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-D ● Specialty Plasma Collected will Support the Company’s Increasin |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal ex |
|
| March 5, 2025 |
KAMADA LTD. INSIDER TRADING POLICY Adopted by the Board of Directors in March 2025 Exhibit 11.1 KAMADA LTD. INSIDER TRADING POLICY Adopted by the Board of Directors in March 2025 This Insider Trading Policy (this “Policy”) provides guidelines and restrictions to all personnel, including directors, officers, employees, including those that are full-time, part-time or employed through third parties, consultants and any other person who receives or has access to material non-public |
|
| March 5, 2025 |
KAMADA LTD. COMPENSATION RECOUPMENT POLICY Effective Date: December 1, 2023 Exhibit 97.1 KAMADA LTD. COMPENSATION RECOUPMENT POLICY Effective Date: December 1, 2023 In the event of any required accounting restatement of the financial statements of Kamada Ltd. (the “Company”) due to the material noncompliance of the Company with any financial reporting requirement under the applicable U.S. federal securities laws or applicable Israeli laws, including any required accountin |
|
| March 5, 2025 |
Exhibit 99.3 March 2025 Fourth Quarter & Year Ended December 31, 2024 Investors Call FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials . This presenta |
|
| March 5, 2025 |
Exhibit 4.43 LEASE AGREEMENT This lease (the “Lease”) is made as of March 7, 2023, 2:41 PM EST (the “Effective Date”) by and between BRIXMOR HOLDINGS 12 SPE, LLC, a Delaware limited liability company (“Landlord”), and KAMADA PLASMA, LLC, a Delaware limited liability company (“Tenant”). In consideration of the mutual covenants contained herein, and other good and valuable consideration, the receipt |
|
| March 5, 2025 |
Exhibit 12.1 I, Amir London, certify that: 1. I have reviewed this annual report on Form 20-F of Kamada Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by t |
|
| March 5, 2025 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Kamada Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2024 as filed with the Securities and Exchange Commission (the “Report”), I, Amir London, Chief Ex |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 5, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements on Form F-3 (File No. 333-274443) and Form S-8 (File Nos 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866) of Kamada Ltd. (the “Company”) of our reports dated March 5, 2025, with respect to the Company’s consolidated financial st |
|
| March 5, 2025 |
Exhibit 2.1 DESCRIPTION OF SECURITIES The descriptions of the securities contained herein summarize the material terms and provisions of the ordinary shares of Kamada Ltd., registered under Section 12 of the Securities Exchange Act of 1934. General Our authorized and registered share capital is NIS 70,000,000 divided into 70,000,000 ordinary shares, nominal (par) value NIS 1.00 each. The Nasdaq Gl |
|
| March 5, 2025 |
I, Chaime Orlev, certify that: Exhibit 12.2 I, Chaime Orlev, certify that: 1. I have reviewed this annual report on Form 20-F of Kamada Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by |
|
| March 5, 2025 |
Exhibit 99.2 Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth ● Record Year with Total 2024 Revenues of $161.0 Million, Representing a 13% Increase over Fiscal Year 2023 and Adjusted EBITDA of $34.1 Million, Up 42% Year-over-Year, and a 21% Margin of Revenues ● Cash Provided by Operating Activities of $47.6 Milli |
|
| March 5, 2025 |
Exhibit 99.1 Kamada Declares Special Cash Dividend of $0.20 Per Share Company Reports Record Revenue and Profitability for Full-Year 2024 REHOVOT, Israel, and HOBOKEN, NJ – March 5, 2025 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma |
|
| March 5, 2025 |
Exhibit 4.42 LEASE AGREEMENT BY AND BETWEEN TCP Las Palmas partners, ltd. (“LANDLORD”) AND KamaDA PLASMA, LLC (“TENANT”) Dated: May 2, 2024 SUMMARY OF LEASE INFORMATION Effective Date: May 2, 2024 Possession Date: Within five (5) business days of the Effective Date but in no event later than June 1, 2024. Commencement Date: The earlier of (a) opening for business in the Premises (which shall mean |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal ex |
|
| March 5, 2025 |
-Confidential- FIFTH AMENDMENT TO SUPPLY AND DISTRIBUTION AGREEMENT Exhibit 4.41 -Confidential- FIFTH AMENDMENT TO SUPPLY AND DISTRIBUTION AGREEMENT This fifth amendment (the “Fifth Amendment”) to the Supply and Distribution Agreement (as defined below) is hereby entered into by and between Kamada Ltd., a corporation organized and existing under the laws of Israel, with its principal office in 2 Holzman Street, Weizmann Science Park, Rehovot 7670402, Israel (“Kama |
|
| February 26, 2025 |
Exhibit 99.1 Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025 Company to Host Conference Call at 8:00am ET REHOVOT, Israel, and HOBOKEN, NJ – February 26, 2025 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the sp |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of February 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| January 22, 2025 |
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America Exhibit 99.1 Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America REHOVOT, Israel, and HOBOKEN, NJ – January 22, 2025 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of January 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| January 8, 2025 |
Exhibit 99.2 Corporate Presentation January 2025 PRO F ITABLE GROWTH THROUGH SPECIALTY PLASMA THERAPIES NASDAQ: KMDA; TASE: KMDA.TA FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any |
|
| January 8, 2025 |
Exhibit 99.1 Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025 · Provides 2025 Annual Guidance of $178 - $182 Million in Revenue and $38 - $42 Million of Adjusted EBITDA, Representing Year-Over-Year Increase of 13% in Revenues and 19% in Adjusted EBITDA Based on Mid-Point of 2024 Annual Guidance · Expects to Achieve 2024 Guidance of $15 |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of January 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of December 2024 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| November 14, 2024 |
KMDA / Kamada Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment SC 13G/A 1 zk2432314.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 17)* Kamada Ltd. (Name of Issuer) Ordinary Shares, par value NIS 1.00 each (Title of Class of Securities) M6240T109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| November 13, 2024 |
Exhibit 99.3 KAMADA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited) AS OF September 30, 2024 TABLE OF CONTENTS Page Condensed Consolidated Statements of Financial Position 1 Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income 2 Condensed Consolidated interim Statements of Changes in Equity 3-7 Condensed Consolidated interim Statements of Cash Flo |
|
| November 13, 2024 |
Exhibit 99.2 November 2024 Third Quarter & Nine Months Ended September 2024 Investors Call FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials . This pr |
|
| November 13, 2024 |
Exhibit 99.1 Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance ● Revenues for Third Quarter of 2024 were $41.7 Million, up 10% Year-over-Year; Nine Month 2024 Total Revenues were $121.9 Million, up 15% Year-over-Year ● Third Quarter 2024 Adjusted EBITDA of $8.8 Million, Representing an 11% Increase Ye |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2024 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| November 6, 2024 |
Exhibit 99.1 Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024 REHOVOT, Israel, and HOBOKEN, NJ – November 6, 2024 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma- |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2024 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| November 4, 2024 |
Kamada to Present at the Stifel 2024 Healthcare Conference Exhibit 99.1 Kamada to Present at the Stifel 2024 Healthcare Conference REHOVOT, Israel, and HOBOKEN, NJ – November 4, 2024 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2024 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| October 21, 2024 |
KAMADA LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.2 KAMADA LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoint(s) Chaime Orlev and Nir Livneh, or either of them, attorneys or attorney of the undersigned, for and in the name(s) of the undersigned, with power of substitution and revocation in each to vote any and all ordinary shares, par value NIS 1.0 per share, of Kamada Ltd. (the “Company”), |
|
| October 21, 2024 |
Exhibit 99.1 KAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: We cordially invite you to attend the Annual General Meeting of Shareholders (the “Meeting”) of Kamada Ltd. (the “Company”) to be held at our offices at 2 Holzman Street, Weizmann Science Park, Rehovot, Israel, on Wednesday, Decemb |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of October 2024 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| September 23, 2024 |
Exhibit 99.1 Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston ● New Plasma Collection Center in Houston Now Open, with Planned Annual Collection Capacity of Approximately 50,000 Liters and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its Full Capacity ● Center Will Collect Normal Source Plasma and Specialty Plas |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of September 2024 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principa |
|
| August 14, 2024 |
Exhibit 99.2 August 2024 Q2 s& H1/2024 Investors Call FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice. It should be noted that some products under develo pme nt described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical tr ial s. This presentation contains forward - looki |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal e |
|
| August 14, 2024 |
Exhibit 99.1 Kamada Reports Strong Second Quarter and First Half 2024 Financial Results with Year-Over-Year 6-Month Top-Line Growth of 18% and a 68% Increase in Profitability ● Revenues for Second Quarter of 2024 were $42.5 Million, up 13% Year-over-Year; First Half 2024 Total Revenues were $80.2 Million, up 18% Year-over-Year ● Second Quarter 2024 Adjusted EBITDA of $9.1 Million, Representing 51% |
|
| August 14, 2024 |
Exhibit 99.3 KAMADA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF June 30, 2024 TABLE OF CONTENTS Page Condensed Consolidated interim Statements of Financial Position F-2 Condensed Consolidated interim Statements of Profit or Loss and Other Comprehensive Income F-3 Condensed Consolidated interim Statements of Changes in Equity F-4 - F-6 Condensed Consolidated interim Statements of |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal e |
|
| August 7, 2024 |
Exhibit 99.1 Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024 Rehovot, Israel, and Hoboken, NJ, August 7, 2024 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty |
|
| May 8, 2024 |
Exhibit 99.1 Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance ● Revenues for First Quarter of 2024 were $37.7 Million, Representing a 23% Increase Year-over-Year ● First Quarter 2024 Adjusted EBITDA of $7.5 Million, Representing a 96% Increase Year-over-Year ● Momentum Prim |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2024 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exec |
|
| May 8, 2024 |
Exhibit 99.2 INVESTORS MEETING NASDAQ & TASE: KMDA May 2024 May 8, 2024 May 8, 2024 Forward - Looking Statement This presentation is not intended to provide investment or medical advice. It should be noted that some products under develo pme nt described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials. This presentat |
|
| May 8, 2024 |
Exhibit 99.3 KAMADA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF MARCH 31, 2024 TABLE OF CONTENTS Page Condensed Consolidated interim Statements of Financial Position 2 Condensed Consolidated interim Statements of Profit or Loss and Other Comprehensive Income 3 Condensed Consolidated interim Statements of Changes in Equity 4-5 Condensed Consolidated interim Statements of Cash Flo |
|
| May 1, 2024 |
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 Exhibit 99.1 Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 Rehovot, Israel, and Hoboken, NJ, May 1, 2024 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2024 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exec |
|
| March 6, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-274443) of Kamada Ltd, and (2) Registration Statement (Form S-8 Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866) pertaining to the 2011 Israeli Share Award Plan of Kam |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2024 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal ex |
|
| March 6, 2024 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Kamada Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2023 as filed with the Securities and Exchange Commission (the “Report”), I, Amir London, Chief Ex |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 6, 2024 |
I, Chaime Orlev, certify that: Exhibit 12.2 I, Chaime Orlev, certify that: 1. I have reviewed this annual report on Form 20-F of Kamada Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by |
|
| March 6, 2024 |
Exhibit 99.1 Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability ● Total Revenues for Fiscal Year 2023 of $142.5 Million, Representing All-Time Record Annual Revenues and Up 10% Compared to Fiscal Year 2022 ● Fiscal Year 2023 Adjusted EBITDA of $24.1 Million, Up 35% Year-over |
|
| March 6, 2024 |
3rd AMENDMENT TO DISTRIBUTION AGREEMENT Exhibit 4.45 -Confidential- 3rd AMENDMENT TO DISTRIBUTION AGREEMENT This 3rd amendment (the “Amendment”) to the Distribution Agreement dated May 20, 2020 (the “Agreement”), by and between Kamada Ltd., a company organized under the laws of the State of Israel, with its principal office in 2 Holzman Street, Weizmann Science Park, Rehovot 7670402, Israel (“Supplier”), and TUTEUR S.A.C.I.F.I.A., with |
|
| March 6, 2024 |
Exhibit 99.2 INVESTORS MEETING NASDAQ & TASE: KMDA March 2024 March 6, 2024 March 6, 2024 Forward - Looking Statement This presentation is not intended to provide investment or medical advice. It should be noted that some products under develo pme nt described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials. This pre |
|
| March 6, 2024 |
KAMADA LTD. COMPENSATION RECOUPMENT POLICY Effective Date: December 1, 2023 Exhibit 4.43 KAMADA LTD. COMPENSATION RECOUPMENT POLICY Effective Date: December 1, 2023 In the event of any required accounting restatement of the financial statements of Kamada Ltd. (the “Company”) due to the material noncompliance of the Company with any financial reporting requirement under the applicable U.S. federal securities laws or applicable Israeli laws, including any required accountin |
|
| March 6, 2024 |
Kamada Issues 2024 CEO Letter to Shareholders Exhibit 99.3 Kamada Issues 2024 CEO Letter to Shareholders Rehovot, Israel, and Hoboken, NJ – March 6, 2024 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief E |
|
| March 6, 2024 |
Exhibit 12.1 I, Amir London, certify that: 1. I have reviewed this annual report on Form 20-F of Kamada Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by t |
|
| February 28, 2024 |
Exhibit 99.1 Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024 Company to Host Conference Call at 8:30am ET Rehovot, Israel, and Hoboken, NJ, February 28, 2024 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serio |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of February 2024 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| February 14, 2024 |
EX-99.1 2 ea193832ex99-1kamada.htm JOINT FILING AGREEMENT, DATED FEBRUARY 14, 2024 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Kamada L |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Kamada Ltd. (Name of Issuer) Ordinary Shares, par value NIS 1.0 per share (Title of Class of Securities) M6240T 109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 12, 2024 |
KMDA / Kamada Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 16)* Kamada Ltd. (Name of Issuer) Ordinary Shares, par value NIS 1.00 each (Title of Class of Securities) M6240T109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| December 28, 2023 |
KMDA / Kamada Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 15)* Kamada Ltd. (Name of Issuer) Ordinary Shares, par value NIS 1.00 each (Title of Class of Securities) M6240T109 (CUSIP Number) December 18, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| December 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of December 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| December 19, 2023 |
KMDA / Kamada Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment SC 13G/A 1 zk2330670.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 14)* Kamada Ltd. (Name of Issuer) Ordinary Shares, par value NIS 1.00 each (Title of Class of Securities) M6240T109 (CUSIP Number) December 14, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of December 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| December 6, 2023 |
Exhibit 99.2 [CERTAIN INFORMATION HAS BEEN EXCLUDED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED] Memorandum of Understanding This binding memorandum of understanding (the “MOU”) is made and entered into on December 4th, 2023 (the “MOU Effective Date”) by and between Kamada Ltd. a company organized under the laws of the State of Israel, with its |
|
| December 6, 2023 |
Exhibit 99.1 Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years ● Largest Commercial Agreement in Kamada’s History Becomes Effective in January 2024 and Includes $180 Million of Revenues to Kamada Over the First Four Years of the Eight Year Term ● Financial Terms Reflect KE |
|
| November 13, 2023 |
Exhibit 99.3 KAMADA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2023 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position 1 Condensed consolidated interim statements of profit or loss and other comprehensive income 2 Condensed consolidated interim statements of changes in equity 3-5 Condensed consolidated interim statements of cash |
|
| November 13, 2023 |
Exhibit 99.2 INVESTORS MEETING NASDAQ & TASE: KMDA November 2023 FORWARD LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials . This presentation contains forward |
|
| November 13, 2023 |
Exhibit 99.1 Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance ● Third Quarter 2023 Revenues were $37.9 Million Representing an 18% Increase Year-over-Year; Nine Month 2023 Revenues of $106.1 Million, Up 26% Year-over-Year ● Third Quarter 2023 Adjusted EBITDA of $7.9 Million Representing a 31% |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| November 13, 2023 |
Exhibit 99.1 KAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: We cordially invite you to attend the Annual General Meeting of Shareholders of Kamada Ltd. (the “Meeting”) to be held at our offices at 2 Holzman Street, Weizmann Science Park, Rehovot, Israel, on Thursday, December 28, 2023, at 4 |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| November 13, 2023 |
KAMADA LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.2 KAMADA LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoint(s) Chaime Orlev and Nir Livneh, or either of them, attorneys or attorney of the undersigned, for and in the name(s) of the undersigned, with power of substitution and revocation in each to vote any and all ordinary shares, par value NIS 1.0 per share, of Kamada Ltd. (the “Company”), |
|
| November 13, 2023 |
Exhibit 99.1 KAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: We cordially invite you to attend the Annual General Meeting of Shareholders of Kamada Ltd. (the “Meeting”) to be held at our offices at 2 Holzman Street, Weizmann Science Park, Rehovot, Israel, on Thursday, December 28, 2023, at 4 |
|
| November 13, 2023 |
KAMADA LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.2 KAMADA LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoint(s) Chaime Orlev and Nir Livneh, or either of them, attorneys or attorney of the undersigned, for and in the name(s) of the undersigned, with power of substitution and revocation in each to vote any and all ordinary shares, par value NIS 1.0 per share, of Kamada Ltd. (the “Company”), |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (A |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| November 8, 2023 |
Exhibit 99.1 Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023 Rehovot, Israel, and Hoboken, NJ, November 8, 2023 - Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the spe |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of October 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| October 16, 2023 |
Exhibit 99.1 Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data ● Following Recent FDA Approval of Technology Transfer Process, CYTOGAM® Manufactured by Kamada at its Facility Now Available for Commercial Sales in U.S. ● New Clinical Data Highlighting Five-year Real-world Sur |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of October 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| October 10, 2023 |
Kamada Provides Corporate Update on its Israel Operations Exhibit 99.1 Kamada Provides Corporate Update on its Israel Operations Rehovot, Israel, and Hoboken, NJ – October 10, 2023 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that while circumstances in Isra |
|
| September 13, 2023 |
September 13, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| September 11, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-3 (Form Type) KAMADA LTD. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Regis |
|
| September 11, 2023 |
As filed with the Securities and Exchange Commission on September 11, 2023 As filed with the Securities and Exchange Commission on September 11, 2023 Registration No. |
|
| September 7, 2023 |
KMDA / Kamada Ltd / DAVIDI ISHAY - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Kamada Ltd. (Name of Issuer) Ordinary Shares, Par Value NIS 1.00 Per Share (Title of Class of Securities) M6240T109 (CUSIP Number) FIMI 6 2016 Ltd. FIMI 7 2020 Ltd. Alon Towers 2, 94 Yigal Alon St., Tel-Aviv 6789141, Israel +(972)-3-565-2244 (Name, Addre |
|
| August 30, 2023 |
Exhibit 99.1 Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds ● Funding Strengthens Kamada’s Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development Opportunities ● Appointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek Rehovot, Israel, |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal e |
|
| August 16, 2023 |
Exhibit 99.2 INVESTORS MEETING NASDAQ & TASE: KMDA August 2023 FORWARD LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials . This presentation contains forward - |
|
| August 16, 2023 |
KAMADA LTD. CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 TABLE OF CONTENTS Exhibit 99.3 KAMADA LTD. CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 TABLE OF CONTENTS Page Consolidated Statements of Financial Position 1 Consolidated Statements of Profit or Loss and Other Comprehensive Income 2 Consolidated Statements of Changes in Equity 3-5 Consolidated Statements of Cash Flows 6-7 Notes to the Interim Consolidated Financial Statements 8-14 - - - - - - - - - - - i |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal e |
|
| August 16, 2023 |
Exhibit 99.1 Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance ● Second Quarter 2023 Revenues were $37.4 Million, Representing a 59% Increase Year-over-Year; First Half 2023 Revenues of $68.2 Million, Up 32% Year-over-Year ● First Half 2023 Adjusted EBITDA of $9.9 Million, Up 24% Year-over-Year ● Robust Second Quarter Res |
|
| August 9, 2023 |
Exhibit 99.1 Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023 Rehovot, Israel, and Hoboken, NJ, August 9, 2023 - Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-d |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal e |
|
| July 13, 2023 |
KAMADA LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.2 KAMADA LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoint(s) Chaime Orlev and Nir Livneh, or either of them, attorneys or attorney of the undersigned, for and in the name(s) of the undersigned, with power of substitution and revocation in each to vote any and all ordinary shares, par value NIS 1.0 per share, of Kamada Ltd. (the “Company”), |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of July 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exe |
|
| July 13, 2023 |
Exhibit 99.1 KAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: We cordially invite you to attend an Extraordinary General Meeting of Shareholders of Kamada Ltd. (the “Meeting”) to be held at our offices at 2 Holzman Street, Weizmann Science Park, Rehovot, Israel, on Tuesday, August 29, |
|
| July 12, 2023 |
Exhibit 99.1 Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S. ● The Extended Agreement Term is Until March 2026 ● The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to Kedrion in 2022 and Anticipates a Significant Increase in 2023 REHOVOT, Israel, and Hoboken, NJ – July 12, 2023 - Kamada Ltd. (NASDAQ: KM |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of July 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exe |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Addres |
|
| May 24, 2023 |
AMENDED AND RESTATED Registration Rights Agreement Exhibit 99.3 AMENDED AND RESTATED Registration Rights Agreement This Amended and Restated Registration Rights Agreement (this “Agreement”) is entered into as of May 23, 2023, by and among KAMADA LTD., a company incorporated under the laws of the State of Israel of 2 Holzman St., Science Park, P.O. Box 4081, Rehovot 7670402, Israel (the “Company”), and the investors listed on Schedule 1 attached he |
|
| May 24, 2023 |
KAMADA LTD. CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2023 TABLE OF CONTENTS Exhibit 99.3 KAMADA LTD. CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2023 TABLE OF CONTENTS Page Consolidated Statements of Financial Position 1 Consolidated Statements of Profit or Loss and Other Comprehensive Income 2 Consolidated Statements of Changes in Equity 3-4 Consolidated Statements of Cash Flows 5-6 Notes to the Interim Consolidated Financial Statements 7-13 - - - - - - - - - - - i |
|
| May 24, 2023 |
Exhibit 99.1 Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary REHOVOT, Israel, and Hoboken, NJ – May 24, 2023 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for r |
|
| May 24, 2023 |
Exhibit 99.2 INVESTORS MEETING NASDAQ & TASE: KMDA May 2023 FORWARD LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials . This presentation contains forward - loo |
|
| May 24, 2023 |
Exhibit 99.2 SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (this “Agreement”) is made as of May 23, 2023, by and among (i) Kamada Ltd., a company organized under the laws of the State of Israel, registration number 51-1524605 (the “Company”), and (ii) FIMI Opportunity 7, L.P., a limited partnership formed under the laws of the State of Delaware (“FIMI Delaware”), and FIMI Israel Opportuni |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exec |
|
| May 24, 2023 |
Exhibit 99.1 Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds Funding to Support Kamada’s Growth Plans and Execution of Strategic Business Development Opportunities REHOVOT, Israel, and Hoboken, NJ – May 24, 2023 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a portfolio of marketed product |
|
| May 24, 2023 |
EX-99 2 exhibit1.htm EXHIBIT 1 EXHIBIT 1 Joint Filing Agreement The undersigned hereby agree that the Schedule 13D (the “Schedule 13D”), filed by the undersigned with respect to Ordinary Shares, par value NIS 1.00 per share, of Kamada Ltd. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securit |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exec |
|
| May 24, 2023 |
Exhibit 99.1 Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance ● Total Revenues for First Quarter of 2023 were $30.7 Million, Up 9% Year-over-Year ● First Quarter 2023 EBITDA of $3.8 Million, Increase of 16% Year-over-Year ● Solid First Quarter Results and Expected Continued Momentum Supported by Multiple Growth Drivers Anticipated to Drive F |
|
| May 24, 2023 |
KMDA / Kamada Ltd / DAVIDI ISHAY - SC 13D/A Activist Investment SC 13D/A 1 zk2329800.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Kamada Ltd. (Name of Issuer) Ordinary Shares, Par Value NIS 1.00 Per Share (Title of Class of Securities) M6240T109 (CUSIP Number) FIMI 6 2016 Ltd. FIMI 7 2020 Ltd. Alon Towers 2, 94 Yigal Alon St., Tel-Aviv 6789141, Isr |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exec |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exec |
|
| May 17, 2023 |
Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023 Exhibit 99.1 Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023 Rehovot, Israel, and Hoboken, NJ, May 17, 2023 - Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that i |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exec |
|
| May 16, 2023 |
Exhibit 99.1 Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland ● Switzerland is the first European country to approve Glassia®, which received U.S. FDA approval in 2010 ● Glassia will be commercialized by IDEOGEN AG in Switzerland and the therapy is expected to be available to patients and providers during the second hal |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exec |
|
| May 3, 2023 |
Exhibit 99.1 Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in Israel ● Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021 with Approximately $23 Million in Revenues in 2022, and Gross Margins Over 50% ● Approval to Manufacture CYTOGAM at Kamada’s Facility to Positively Impact Plant Utilization and Efficiency Rehovot |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 15, 2023 |
I, Chaime Orlev, certify that: Exhibit 12.2 I, Chaime Orlev, certify that: 1. I have reviewed this annual report on Form 20-F of Kamada Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by |
|
| March 15, 2023 |
Exhibit 4.39 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [*****] indicates the redacted confidential portions of this exhibit. July 4, 2022 Kamada Ltd. (“Kamada”) Via Email TUTEUR S.A. 25 de Mayo 455 11400 Montevideo Uruguay Re: Letter Agreement Reference is made to |
|
| March 15, 2023 |
Q4/FY’22 Financial Results Conference Call NASDAQ & TASE: KMDA March 15, 2023 Exhibit 99.2 Q4/FY’22 Financial Results Conference Call NASDAQ & TASE: KMDA March 15, 2023 FORWARD LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials . This pres |
|
| March 15, 2023 |
6-K 1 ea175225-6kkamadaltd.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Par |
|
| March 15, 2023 |
Exhibit 99.1 Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth ● Total Revenues for Fiscal Year 2022 of $129.3 Million Represented Growth of 25% Compared to Fiscal Year 2021; Fourth Quarter 2022 Revenues of $45.4 Million Represented a 44% Increase Year-over-Year ● Fiscal Year 2022 EBITDA of $17.8 mi |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal ex |
|
| March 15, 2023 |
KAMADA LTD. COMPENSATION POLICY FOR DIRECTORS Exhibit 4.24 KAMADA LTD. COMPENSATION POLICY FOR DIRECTORS 1. Purpose This Compensation Policy (the “Policy”) constitutes the Compensation Policy (as such term is defined in the Companies Law) of Kamada Ltd. (the “Company”) with respect to the determination of Terms of Office and Engagement of non-employee members of the Board of Directors of the Company (each, a “Director”), if and to the extent |
|
| March 15, 2023 |
Exhibit 4.37 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [*****] indicates the redacted confidential portions of this exhibit. AMENDED AND RESTATED MANUFACTURING SERVICES AGREEMENT BY AND BETWEEN EMERGENT BIOSOLUTIONS INC. AND APTEVO THERAPEUTICS INC. DATED AS OF SE |
|
| March 15, 2023 |
Kamada Issues 2023 CEO Letter to Shareholders Exhibit 99.1 Kamada Issues 2023 CEO Letter to Shareholders Rehovot, Israel, and Hoboken, NJ – March 15, 2023 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief |
|
| March 15, 2023 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos 333-192720, 333-207933, 333-215983, 333- 222891, 333-233267 and 333-265866) pertaining to the 2011 Israeli Share Plan of Kamada Ltd. of our reports dated March 15, 2023, with respect to the consolidated financial statements of Kamada Ltd. a |
|
| March 15, 2023 |
Exhibit 12.1 I, Amir London, certify that: 1. I have reviewed this annual report on Form 20-F of Kamada Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by t |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal ex |
|
| March 15, 2023 |
2nd AMENDMENT TO DISTRIBUTION AGREEMENT Exhibit 4.40 -Confidential- CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [*****] indicates the redacted confidential portions of this exhibit. 2nd AMENDMENT TO DISTRIBUTION AGREEMENT This 2nd amendment (the “Amendment”) to the Distribution Agreement dated May 20, 202 |
|
| March 15, 2023 |
Kamada Files Annual Report for the Year Ended December 31, 2022 Exhibit 99.1 Kamada Files Annual Report for the Year Ended December 31, 2022 REHOVOT, Israel, and Hoboken, NJ – March 15, 2023 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it has filed its annual |
|
| March 15, 2023 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Kamada Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2022 as filed with the Securities and Exchange Commission (the “Report”), I, Amir London, Chief Ex |
|
| March 15, 2023 |
CONTRACT MANUFACTURING, SERVICES AND SUPPLY AGREEMENT Exhibit 4.38 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [*****] indicates the redacted confidential portions of this exhibit. CONTRACT MANUFACTURING, SERVICES AND SUPPLY AGREEMENT This Contract Manufacturing, Services and Supply Agreement (the “Agreement”) is made |
|
| March 15, 2023 |
KAMADA LTD. COMPENSATION POLICY FOR EXECUTIVE OFFICERS Exhibit 4.23 KAMADA LTD. COMPENSATION POLICY FOR EXECUTIVE OFFICERS 1. Purpose This Compensation Policy (the “Policy”) constitutes the Compensation Policy (as such term is defined in the Companies Law) of Kamada. Ltd. (the “Company”) with respect to the determination of Terms of Office and Engagement of Office Holders (as such term is defined in the Companies Law), other than non-employee director |
|
| March 15, 2023 |
Exhibit 4.25 ISRAELI SHARE AWARD PLAN KAMADA LTD. THE 2011 ISRAELI SHARE AWARD PLAN (*In compliance with Amendment No. 132 of the Israeli Tax Ordinance, 2002) ISRAELI SHARE AWARD PLAN This plan, as amended from time to time, shall be known as Kamada Ltd. 2011 Israeli Share Award Plan (the “ISAP”). 1. PURPOSE OF THE ISAP The ISAP is intended to provide an incentive to retain, in the employ of the C |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal ex |
|
| March 9, 2023 |
Exhibit 99.1 Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023 Rehovot, Israel, and Hoboken, NJ, March 9, 2023 - Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, toda |
|
| February 14, 2023 |
KMDA / Kamada Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment SC 13G/A 1 zk2329245.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 13)* Kamada Ltd. (Name of Issuer) Ordinary Shares, par value NIS 1.00 each (Title of Class of Securities) M6240T109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| January 4, 2023 |
Exhibit 99.1 Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in Israel ● FDA Approval Currently Expected by Mid-2023 ● Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021, with Gross Margins Over 50% ● Ability to Manufacture CYTOGAM at Kamada’s Facility to Positively Impact Plant Utilization and Efficiency Rehovot |
|
| January 4, 2023 |
6-K 1 ea171189-6kkamada.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of January 2023 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of December 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant?s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| December 19, 2022 |
Kamada Announces Planned Transition of Chief Financial Officer Exhibit 99.1 Kamada Announces Planned Transition of Chief Financial Officer Rehovot, Israel, and Hoboken, NJ – December 19, 2022 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that its Chief Financial Officer (CFO), Chaime Orlev, will transition out of his role to pursue other |
|
| December 19, 2022 |
6-K 1 ea170429-6kkamada.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of December 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Par |
|
| November 22, 2022 |
KAMADA LTD. CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022 TABLE OF CONTENTS Exhibit 99.2 KAMADA LTD. CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022 TABLE OF CONTENTS Page Consolidated Statements of Financial Position 2 Consolidated Statements of Profit or Loss and Other Comprehensive Income 3 Consolidated Statements of Changes in Equity 4-6 Consolidated Statements of Cash Flows 7-8 Notes to the Interim Consolidated Financial Statements 9-16 - - - - - - - - - - |
|
| November 22, 2022 |
Exhibit 99.1 Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance ● Third Quarter 2022 Revenues of $32.2 Million, a 40% Increase Compared to Prior Year Period; Reaping the Benefits of the Acquired IgG Portfolio ● Strong Results Represent Completion of the Company’s Strategic Transformation into a Diversified Comm |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (A |
|
| November 17, 2022 |
Kamada Ltd. 2011 Israeli Share Award Plan Appendix – U.S. Tax Payer Exhibit 99.3 KAMADA LTD. 2011 ISRAEL SHARE AWARD PLAN APPENDIX – U.S. TAXPAYERS 1. Special Provisions for Persons who are U.S. Taxpayers. 1.1 This Appendix – U.S. Taxpayers (this “Appendix”) to the Kamada Ltd. 2011 Israel Share Award Plan (the “ISAP”) was approved by the Board of Directors of Kamada Ltd. (the “Board”) on February 28, 2022 (the “Effective Date”). Subject to Section 1.4 hereof and S |
|
| November 17, 2022 |
Updated Compensation Policy for Directors Exhibit 99.2 KAMADA LTD. COMPENSATION POLICY FOR DIRECTORS 1. Purpose This Compensation Policy (the “Policy”) constitutes the Compensation Policy (as such term is defined in the Companies Law) of Kamada Ltd. (the “Company”) with respect to the determination of Terms of Office and Engagement of non-employee members of the Board of Directors of the Company (each, a “Director”), if and to the extent |
|
| November 17, 2022 |
Updated Compensation Policy for Executive Officers EX-99.1 2 ea168893ex99-1kamadaltd.htm UPDATED COMPENSATION POLICY FOR EXECUTIVE OFFICERS Exhibit 99.1 KAMADA LTD. COMPENSATION POLICY FOR EXECUTIVE OFFICERS 1. Purpose This Compensation Policy (the “Policy”) constitutes the Compensation Policy (as such term is defined in the Companies Law) of Kamada. Ltd. (the “Company”) with respect to the determination of Terms of Office and Engagement of Office |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| November 16, 2022 |
Exhibit 99.1 Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022 Rehovot, Israel, and Hoboken, NJ, November 16, 2022 - Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial |
|
| November 8, 2022 |
Exhibit 99.1 KAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: We cordially invite you to attend the Annual General Meeting of Shareholders of Kamada Ltd. (the “Meeting”) to be held at our offices at 2 Holzman Street, Weizmann Science Park, Rehovot, Israel, on Thursday, December 22, 2022, at 2 |
|
| November 8, 2022 |
6-K 1 f6k1122kamadaltd.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Re |
|
| November 8, 2022 |
KAMADA LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.2 KAMADA LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoint(s) Chaime Orlev and Yifat Philip, or either of them, attorneys or attorney of the undersigned, for and in the name(s) of the undersigned, with power of substitution and revocation in each to vote any and all ordinary shares, par value NIS 1.0 per share, of Kamada Ltd. (the “Company”) |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| November 7, 2022 |
Exhibit 99.1 Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT ● Trial Recruitment Beginning to Accelerate; 30 Patients Enrolled and Treated to Date ● Independent Data Safety Monitoring Board (DSMB) Recommends Study Continuation Without Modification for Fourth Time Since Study Initiation ● Based on Encouraging Safety Observed to Date, Trial |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of October 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| October 26, 2022 |
Kamada to Present at the Credit Suisse 31st Annual Healthcare Conference Exhibit 99.1 Kamada to Present at the Credit Suisse 31st Annual Healthcare Conference REHOVOT, Israel, and Hoboken, NJ, – October 26, 2022 – Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that Amir London, Chief Executive Officer, will present a corporate overview at the Credit Suisse 31 |
|
| October 19, 2022 |
6-K 1 ea167280-6kkamadaltd.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of October 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science P |
|
| October 19, 2022 |
Kamada Awarded $22 Million Extension of Canadian Supply Tender Exhibit 99.1 Kamada Awarded $22 Million Extension of Canadian Supply Tender ? Awarded Extension to Existing Supply Tender which relates to Portfolio of Four Specialty IgG Products Acquired in 2021 ? Supply Extension Secures Ongoing Sales of Approximately $7.5 Million Per Year for 2023-2025, with an Option to Extend for up to Additional Two Years Rehovot, Israel, and Hoboken, NJ, October 19, 2022 ? |
|
| August 17, 2022 |
KAMADA LTD. CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 TABLE OF CONTENTS Exhibit 99.2 KAMADA LTD. CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 TABLE OF CONTENTS Page Consolidated Statements of Financial Position 2 Consolidated Statements of Profit or Loss and Other Comprehensive Income 3 Consolidated Statements of Changes in Equity 4-6 Consolidated Statements of Cash Flows 7-8 Notes to the Interim Consolidated Financial Statements 9-15 - - - - - - - - - - - KA |
|
| August 17, 2022 |
Exhibit 99.1 Kamada Reports Second Quarter and First Half 2022 Financial Results; Significant Growth Driven by Multiple Catalysts Expected in Second Half of 2022; Reiterates 2022 Revenue and Profitability Guidance ? Second Quarter 2022 Revenues were $23.6 Million; First Half 2022 Revenues of $51.7 Million Increased 5% Year-Over-Year ? First Half 2022 Adjusted EBITDA of $4.6 Million; Excluding Labo |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant?s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal e |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of August 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant?s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal e |
|
| August 10, 2022 |
Exhibit 99.1 Kamada to Announce Second Quarter and First Half Ended June 30, 2022 Financial Results and Host Conference Call on August 17, 2022 Rehovot, Israel, and Hoboken, NJ - August 10, 2022 - Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for t |
|
| July 15, 2022 |
6-K 1 ea162860-6kkamadaltd.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of July 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park |
|
| July 15, 2022 |
Exhibit 99.1 Kamada Announces Resolution the Labor Strike at the Company?s Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed REHOVOT, Israel ? July 15, 2022 - Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that the Company, the Employees? Union of Kamada? |
|
| July 6, 2022 |
Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement Exhibit 99.1 Kamada Announces $11.4 Million International VARIZIG? Procurement Agreement ? Procurement Agreement Following a New Tender Won from an International Organization Operating Principally in Latin America ? Product Supply Expected During the Fourth Quarter of 2022 and the First Half of 2023 Rehovot, Israel, and Hoboken, NJ, July 6, 2022 - Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically in |
|
| July 6, 2022 |
6-K 1 ea162494-6kkamada.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of July 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P |
|
| June 28, 2022 |
As filed with the Securities and Exchange Commission on June 28, 2022 As filed with the Securities and Exchange Commission on June 28, 2022 Registration No. |
|
| June 28, 2022 |
Exhibit 107 FILING FEE TABLE FORM S-8 (Form Type) Kamada Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Securities Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value NIS 1.00(3) Other 1, |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of June 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant?s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exe |
|
| June 15, 2022 |
Exhibit 99.1 Kamada Strengthens Senior Leadership Team; Furthering Commitment as a Fully Integrated Global Leader in the Specialty Plasma Derived Therapeutics Market Rehovot, Israel, and Hoboken, NJ, June 15, 2022 - Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today the promotions of Shavit |
|
| June 1, 2022 |
6-K 1 ea160928-6kkamada.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of June 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P |
|
| June 1, 2022 |
Kamada to Host a Virtual Analysts and Investors Meeting to Review its Growth Catalysts Exhibit 99.1 Kamada to Host a Virtual Analysts and Investors Meeting to Review its Growth Catalysts Rehovot, Israel, June 1, 2022 ? Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will host a virtual analysts and investors meeting on Tuesday, June 7, 2022, at 12:00 PM Eastern Time |
|
| May 17, 2022 |
Exhibit 99.1 Kamada Reports First Quarter 2022 Financial Results; Reiterates Revenue and Profitability Guidance with Significant Growth Expected in 2022 ? First Quarter 2022 Revenues were $28.1 Million, Up 13% Year Over Year. ? Kamada Reiterates Fiscal Year 2022 Revenue Guidance of $125 - $135 Million, Representing a 20% to 30% Increase over 2021 and EBITDA Margins Anticipated Between 12%-15%, Mor |
|
| May 17, 2022 |
KAMADA LTD. CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2022 TABLE OF CONTENTS Exhibit 99.2 KAMADA LTD. CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2022 TABLE OF CONTENTS Page Consolidated Statements of Financial Position 2 Consolidated Statements of Profit or Loss and Other Comprehensive Income 3 Consolidated Statements of Changes in Equity 4-5 Consolidated Statements of Cash Flows 6-7 Notes to the Interim Consolidated Financial Statements 8-14 - - - - - - - - - - - 1 |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal exec |
|
| May 17, 2022 |
Exhibit 99.1 Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification REHOVOT, Israel ? May 17, 2022 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, |
|
| May 17, 2022 |
6-K 1 ea160091-6kkamadaltd.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, |
|
| May 11, 2022 |
6-K 1 ea159734-6kkamadaltd.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of May 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, |
|
| May 11, 2022 |
Exhibit 99.1 Kamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022 Rehovot, Israel, May 11, 2022 - Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the first quarter ended March 31, 2022, |
|
| April 26, 2022 |
6-K 1 ea158868-6kkamadaltd.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of April 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Par |
|
| April 26, 2022 |
Exhibit 99.1 Kamada Ltd. (the ?Company?) (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, today announced that on April 26, 2022, during the course of the Company?s negotiations with the Histadrut - General Federation of Labor in Israel (the ?Histadrut?) and the Employees? Committee of Kamada?s Beit Kama production facility in Israel (the ?Employee?s Committee?), on |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal ex |
|
| March 15, 2022 |
Kamada Ltd. 2011 Israeli Share Award Plan. Exhibit 4.25 ISRAELI SHARE AWARD PLAN KAMADA LTD. THE 2011 ISRAELI SHARE AWARD PLAN (*In compliance with Amendment No. 132 of the Israeli Tax Ordinance, 2002) ISRAELI SHARE AWARD PLAN This plan, as amended from time to time, shall be known as Kamada Ltd. 2011 Israeli Share Award Plan (the ?ISAP?). 1. PURPOSE OF THE ISAP The ISAP is intended to provide an incentive to retain, in the employ of the C |
|
| March 15, 2022 |
Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a). Exhibit 12.2 I, Chaime Orlev, certify that: 1. I have reviewed this annual report on Form 20-F of Kamada Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by |
|
| March 15, 2022 |
6-K 1 ea156887-6kkamadaltd.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Par |
|
| March 15, 2022 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Kamada Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, Amir London, Chief Ex |
|
| March 15, 2022 |
Consent of Ernst & Young Global, independent registered public accounting firm. EX-15.1 8 f20f2021ex15-1kamadaltd.htm CONSENT OF ERNST & YOUNG GLOBAL, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement on Form S-8 (File Nos 333-192720, 333-207933, 333-215983, 333-222891 and 333-233267) of Kamada Ltd. (the “Company”) of our reports dated M |
|
| March 15, 2022 |
Exhibit 99.1 Kamada Reports Fiscal Year and Fourth Quarter 2021 Financial Results; Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022 ? Total Revenues for Fiscal Year 2021 were $103.6 Million and Fourth Quarter 2021 Revenues were $31.5 Million. ? Fiscal Year 2022 Revenues are Expected to Range Between $125 Million to $135 Million, Representing a 20% to 30% Increas |
|
| March 15, 2022 |
Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a). Exhibit 12.1 I, Amir London, certify that: 1. I have reviewed this annual report on Form 20-F of Kamada Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by t |
|
| March 15, 2022 |
Kamada Issues 2022 CEO Letter to Shareholders Exhibit 99.1 Kamada Issues 2022 CEO Letter to Shareholders REHOVOT, Israel ? March 15, 2022 - Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today issued the Letter to Shareholders from Amir London, Chief Executive Officer. March 15th, 2022 Dear Shareholders, Colleagues and Business Partners: Th |
|
| March 15, 2022 |
Kamada Ltd. 2011 Israeli Share Award Plan Appendix – U.S. Taxpayer. EX-4.26 3 f20f2021ex4-26kamadaltd.htm KAMADA LTD. 2011 ISRAELI SHARE AWARD PLAN APPENDIX - U.S. TAXPAYER KAMADA LTD. 2011 ISRAEL SHARE AWARD PLAN APPENDIX – U.S. TAXPAYERS 1. Special Provisions for Persons who are U.S. Taxpayers. 1.1 This Appendix – U.S. Taxpayers (this “Appendix”) to the Kamada Ltd. 2011 Israel Share Award Plan (the “ISAP”) was approved by the Board of Directors of Kamada Ltd. (t |
|
| March 15, 2022 |
Kamada Files Annual Report for the Year Ended December 31, 2021 Exhibit 99.1 Kamada Files Annual Report for the Year Ended December 31, 2021 Rehovot, Israel, March 15, 2022 ? Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021, with the U.S. Securities and Exchang |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal ex |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 14, 2022 |
Kamada Expands U.S. Leadership Team with Two Key Appointments Exhibit 99.1 Kamada Expands U.S. Leadership Team with Two Key Appointments ? New Executives to Strengthen the Company?s U.S. Commercial Operations, Focused on Recently Acquired Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Products, and Planned Opening of New Plasma Collection Centers REHOVOT, Israel ? March 14, 2022 ? Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated |
|
| March 14, 2022 |
6-K 1 ea156810-6kkamadaltd.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Par |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal ex |
|
| March 3, 2022 |
EXHIBIT 99.1 Kamada Ltd. (the “Company”) (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that on March 3, 2022, during the course of the Company’s negotiations with the Histadrut - General Federation of Labor in Israel (the “Histadrut”) and the Employees’ Committee of Kamada’s Beit Kama production facility in Israel (the “Employee’s Committee”), on the extension |
|
| March 2, 2022 |
Exhibit 99.1 Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2021 Financial Results, and Host Conference Call on March 15, 2022 Rehovot, Israel, March 2, 2022 - Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021, prior to the open of t |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2022 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant?s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal ex |
|
| February 7, 2022 |
Exhibit 1 [Unofficial Translation] December 12, 2019 Powers of Signature in The Phoenix Holdings Ltd. |
|
| February 7, 2022 |
KMDA / Kamada Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 12)* Kamada Ltd. (Name of Issuer) Ordinary Shares, par value NIS 1.00 each (Title of Class of Securities) M6240T109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| December 16, 2021 |
Exhibit 99.1 KAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel Notice of Results of the 2021 Annual General Meeting of Shareholders held on December 16, 2021 Kamada Ltd. (the ?Company?) today announced that all of the proposals presented for approval at its 2021 Annual General Meeting of Shareholders held on December 16, 2021 at the Company?s offices in Rehov |
|
| December 16, 2021 |
6-K 1 ea152388-6kkamadaltd.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of December 2021 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science |
|
| November 22, 2021 |
KAMADA LTD. CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 TABLE OF CONTENTS Exhibit 99.2 KAMADA LTD. CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 (Unaudited) TABLE OF CONTENTS Page Consolidated Statements of Financial Position 2 Consolidated Statements of Profit or Loss and Other Comprehensive Income 3 Consolidated Statements of Changes in Equity 4-7 Consolidated Statements of Cash Flows 8-9 Notes to the Interim Consolidated Financial Statements 10-20 - - - |
|
| November 22, 2021 |
EX-99.2 3 ea151143ex99-2kamadaltd.htm ASSET PURCHASE AGREEMENT AMONG SAOL INTERNATIONAL LIMITED, SAOL BERMUDA LIMITED, SAOL THERAPEUTICS RESEARCH LIMITED, SAOL THERAPEUTICS INC., SAOL US INC., KAMADA LIMITED AND KAMADA INC Exhibit 99.2 ASSET PURCHASE AGREEMENT AMONG Saol International Limited, Saol BERMUDA limited, SAOL THERAPEUTICS RESEARCH LIMITED, SAOL THERAPEUTICS INC., Saol US Inc., KAMADA LI |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2021 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant?s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2021 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant?s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal |
|
| November 22, 2021 |
Exhibit 99.1 Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products ? Third Quarter 2021 Revenues were $23.0 Million and Total Revenues for the First Nine Months of 2021 were $72.2 Million ? Kamada has Acquired a Portfolio of Four FDA-Approved Plasma- |
|
| November 22, 2021 |
EX-99.1 2 ea151143ex99-1kamadaltd.htm KAMADA ANNOUNCES STRATEGIC TRANSFORMATIONAL TRANSACTION POSITIONING THE COMPANY AS A GLOBAL LEADER IN THE PLASMA-DERIVED HYPERIMMUNE MARKET THROUGH THE ACQUISITION OF A PORTFOLIO OF FOUR FDA-APPROVED COMMERCIAL PRODUCTS Exhibit 99.1 Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimm |
|
| November 9, 2021 |
Exhibit 1 [Unofficial Translation] December 12, 2019 Powers of Signature in The Phoenix Holdings Ltd. |
|
| November 9, 2021 |
KMDA / Kamada Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment SC 13G/A 1 zk2126778.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 11)* Kamada Ltd. (Name of Issuer) Ordinary Shares, par value NIS 1.00 each (Title of Class of Securities) M6240T109 (CUSIP Number) November 4, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| November 8, 2021 |
Kamada to Announce Third Quarter Financial Results and Host Conference Call on November 22, 2021 Exhibit 99.1 Kamada to Announce Third Quarter Financial Results and Host Conference Call on November 22, 2021 Rehovot, Israel, November 8, 2021 - Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the three and nine months ended September 30, 2021, prior to the open of the U.S. financial markets on Monday, Novem |
|
| November 8, 2021 |
6-K 1 ea150107-6kkamada.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of November 2021 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Par |
|
| November 4, 2021 |
EX-99.1 2 ea149875ex99-1kamada.htm NOTICE AND PROXY STATEMENT FOR THE 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 16, 2021 Exhibit 99.1 KAMADA LTD. 2 Holzman Street Weizmann Science Park P.O. Box 4081 Rehovot 7670402, Israel NOTICE OF 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS Dear Shareholder: We cordially invite you to attend the 2021 Annual General Meeting of Shareholder |
